S. Chaney

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

John H. Kehne, B M Baron, A A Carr et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 359 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Performance deficits of mGluR8 knockout mice in learning tasks: the effects of null mutation and the background genotype

Robert Gerlai, Benjamin Adams, T. E. Fitch et al. · Neuropharmacology · 2002 · 65 citations

Life Sciences, Neurobiology, Neuroscience +10

Preclinical findings predicting efficacy and side‐effect profile of <scp>LY</scp> 2940094, an antagonist of nociceptin receptors

Jeffrey M. Witkin, Linda M. Rorick‐Kehn, Mark J. Benvenga et al. · Pharmacology Research & Perspectives · 2016 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

COVID-19 and hydroxychloroquine side-effects: glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia

S. Chaney, A Basirat, Robert J. McDermott et al. · QJM · 2020 · 14 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +11